Advertisements


NEJM publishes results from phase 2 study of vaccines reducing TB infections

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJul 11th, 2018

Genentech Phase III HAVEN 3 study results published in NEJM

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 30th, 2018

VBI Vaccines announces "positive" final Phase 1 study results for VBI-1501

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 10th, 2018

Ionis Pharmaceuticals announces results from Phase 2 study of AKCEA-APO-L

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewall13 hr. 32 min. ago

Johnson & Johnson"s Janssen discloses phase 3 study results of Esketamine

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 21st, 2018

Galectin"s GR-MD-02 Positive in Phase Ib Study With Keytruda

Galectin Therapeutics (GALT) posts favorable results from a phase Ib study on GR-MD-02 combined with Merck's Keytruda for treating metastatic melanoma. Shares of Galectin Therapeutics, Inc. GALT rallied 14.5% fo.....»»

Category: smallbizSource: nytSep 21st, 2018

Progenics Pharma"s Stock Down on Dismal Phase III Study Data

Progenics Pharmaceuticals' (PGNX) shares down on disappointing results from phase III study evaluating imaging agent, 1404, for prostate cancer detection. .....»»

Category: worldSource: nytSep 20th, 2018

44 Stocks Moving In Tuesday"s Mid-Day Session

Gainers Viking Therapeutics, Inc. (NASDAQ: VKTX) climbed 87.8 percent to $19.51 after announcing top-line results from Phase 2 study of VK2809. The study achieved primary endpoint. read more.....»»

Category: blogSource: benzingaSep 18th, 2018

22 Stocks Moving In Tuesday"s Pre-Market Session

Gainers Viking Therapeutics, Inc. (NASDAQ: VKTX) rose 135.8 percent to $24.50 in pre-market trading after announcing top-line results from Phase 2 study of VK2809. The study achieved primary endpoint. read more.....»»

Category: blogSource: benzingaSep 18th, 2018

Viking Therapeutics announces results from Phase 2 study of VK2809

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 18th, 2018

Atossa Genetics (ATOS) CEO Steve Quay on Preliminary Results from Male Phase 1 Study of Topical Endoxifen Conference (Transcript)

Atossa Genetics (ATOS) CEO Steve Quay on Preliminary Results from Male Phase 1 Study of Topical Endoxifen Conference (Transcript).....»»

Category: topSource: seekingalphaSep 13th, 2018

Acadia publishes additional data from Phase 2 study of pimavanserin

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 10th, 2018

JAMA publishes Phase III study using 22nd Century"s SPECTRUM cigarettes

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 5th, 2018

Xenon Pharmaceuticals" XEN1101 shows "positive" results in Phase 1b study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 29th, 2018

Pfizer presents Tafamidis Phase 3 Transthyretin Cardiomyopathy study results

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 27th, 2018

Esperion presents results of Phase 3 long-term study of Bempedoic Acid

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 25th, 2018

AbbVie announces "positive" results from Phase 3 ELARIS UF-EXTEND study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 22nd, 2018

Glaxo, J&J"s Dual Drug HIV Regimen Succeeds in Phase III Study

Glaxo (GSK) and Johnson and Johnson report positive top line results from a late-stage study of their injectable two-drug regimen for the treatment of HIV. GlaxoSmithKline’s GSK HIV drug subsidiary-ViiV H.....»»

Category: smallbizSource: nytAug 17th, 2018

Strongbridge Biopharma: "positive" results from Phase 3 SONICS study of RECORLEV

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 8th, 2018

Protagonist announces results from re-analysis fo Phase 2 Propel study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 6th, 2018

Arbutus Reports 2018 Second Quarter Financial Results and Provides Corporate Update

- Phase 1a/1b study of AB-506, a second-generation oral capsid inhibitor, initiated - Phase 1a/1b study of AB-452, a novel and proprietary oral RNA destabilizer, expec.....»»

Category: earningsSource: benzingaAug 2nd, 2018